Prognostic value of quantitative liver function tests in viral cirrhosis: A prospective study

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 7, 2006, Pages 713-720

  Addario, Luigi ^a   Scaglione, Giuseppe ^b   Tritto, Giovanni ^a   Di Costanzo, Giovan Giuseppe ^a   De Luca, Massimo ^a   Lampasi, Filippo ^a   Galeota Lanza, Alfonso ^a   Picciotto, Francesco P ^a   Teresa Tartaglione, Maria ^a   Utech, Wanda ^a   Macrì, Michela ^a   Giannelli, Eduardo ^a   Ascione, Antonio ^a,c  

^a CARDARELLI HOSPITAL   (Italy)

^b G RUMMO HOSPITAL   (Italy)

^c NONE   (Italy)

Author keywords

Child Turcotte Pugh; Galactose elimination Capacity; Liver cirrhosis; Liver transplantation; Model for End Stage Liver Disease; Monoethylglycinexylidide; Prognosis

Indexed keywords

DEETHYLLIDOCAINE; LIDOCAINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEATH; FEMALE; GALACTOSE ELIMINATION CAPACITY; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL;

ADULT; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; GALACTOSE; HEPATITIS, VIRAL, HUMAN; HUMANS; LIDOCAINE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 33745268238     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000219104.40435.43     Document Type: Article

References (42)

1. Schlicting P, Christensen E, Andersen PK, Fauerholdt L, Juhl E, Poulsen H, et al. Copenhagen Study Group for Liver Disease. Prognostic factors in cirrhosis identifies by Cox's regression model. Hepatology 1983; 3:889-895.
2. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 37:468-475.
3. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical statistical validity of conventional prognostic factor in predicting short term survival among cirrhotics. Hepatology 1987; 7:660-664.
4. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-470.
5. Child C, Turcotte J. Surgery and portal hypertension. In: Child CG, editor. The liver and portal hypertension. Philadelphia, PA: Saunders; 1964. p. 50.
6. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
7. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen P, Juhl E, et al. Prognostic value of Child Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4:430-435.
8. DeJong FE, Janssen HLA, DeMan RA, Hop WCJ, Schalm SW, Van Blankestein M. Survival and prognostic indicators in hepatitis B surface antigen positive cirrhosis of the liver. Gastroenterology 1992; 103:1630-1635.
9. Degre D, Bourgeois N, Boon N, Le Moine O, Luois H, Donckier V, et al. Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation. Transpl Int 2004; 17:31-38.
10. Bircher J. Quantitative assessment of deranged hepatic function: a missed opportunity? Semin Liver Dis 1983; 3:275-284.
11. Branch RA. Drugs as indicators of hepatic function. Hepatology 1982; 2:97-105.
12. Di Costanzo GG, Ascione A. How to quantitate liver function. In: Ascione A, editor. Hepatology at bedside. Napoli: Arte Tipografica Editrice; 2003. pp. 39-51.
13. Craxì A, Almasio P. How to explore liver function. In: Ascione A, editor. Hepatology at bedside. Napoli: Arte Tipografica Editrice; 2003. pp. 23-38.
14. Tygstrup N, Andersen P, Thompsen BL. Prognostic evaluation in alcoholic cirrhosis. Acta Med Scand 1986; 703:149-153.
15. Kurz G, Wallafalz K. D-galactose, W-test und galactose dehydrogenase. In: Bergmeyer HU, editor. Metoden der Enzymatischen Analyse. 2nd ed. Weinheim: Verlag Chemie; 1970. pp. 1241-1249.
16. Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scand J Clin Lab Invest 1966; 18 (suppl 92):118-125.
17. Arrigoni A, Gindro T, Aimo G, Cappello N, Meloni A, Benedetti P, et al. Monoethylglycinexylidide test: a prognostic indicator of survival in cirrhosis. Hepatology 1994; 20:383-387.
18. Oellerich M, Burdelski M, Lautz HU, Rodeck B, Duewel J, Schulz M, et al. Assessment of pretransplant prognosis patients with cirrhosis. Transplantation 1991; 51:801-806.
19. Albers I, Hartmann H, Bircher J, Creutzfeld W. Superiority of Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989; 24:269-276.
20. Botta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003; 52:134-139.
21. Lladò L, Figueras J, Memba R, Xiol X, Baliellas C, Vazquez S, et al. Is MELD really the definitive score for liver allocation? Liver Transpl 2002; 8:795-798.
22. Salerno F, Borroni G, Moser P, Sangiovanni A, Almasio P, Budillon G, et al. Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. AISF Group for the study of liver transplantation. J Hepatol 1996; 25:474-480.
23. Conti F, Dousset B, Cherruau B, Jguerin C, Soubrance O, Houssin D, et al. Use of lidocaine metabolism to test liver function during the long-term follow-up of liver transplant recipients. Clin Transplant 2004; 18:235-241.
24. Ravaioli M, Grazi GL, Principe A, Ercolani G, Cescon M, Gardini A, et al. Operative risk by the lidocaine test (MEGX) in resected for HCC on chirrosis. Hepatogastroenterology 2003; 50:1552-1555.
25. Redaelli CA, Dufour JF, Wagner M, Schilling M, Husler J, Krahenbbuhl L, et al. Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg 2002; 235:77-85.
26. Schmidt LE, Ott P, Tygstrup N. Galactose elimination capacity as a prognostic marker in patients with severe acetaminophen hepatotoxicity: 10 years'experience. Clin Gastroenterol Hepatol 2004; 2:418-424.
27. Ranek L, Andreasen PB, Tygstrup N. Galactose elimination capacity as a prognostic index in patients with fulminant liver failure. Gut 1976; 17:959-964.
28. Reichen J, Bianchi L, Buheler H, Dolivo N, Gonvers JJ, Lavanchy D, et al. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver. J Hepatol 1996; 25:275-282.
29. Giannini E, Fasoli A, Romagnoli P, Botta F, Fumagalli A, Polegato S, et al. Monitoring of liver metabolic function during interferon-alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients. Hepatogastroenterology 2002; 49:778-782.
30. Huang YS, Chiang JH, Wu JC, Chang FY, Lee SD. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol 2002; 97:1223-1227.
31. Schaad HJ, Frey BM, Renner EL, Preisig R, Frey FJ. Microsomal liver function declines steadily after kidney grafting: a three to five year follow-up. Kidney Int 1992; 41:420-427.
32. Meyer B, Luo H, Bargetzi M, Renner EL, Stalder GA. Quantitation of intrinsic drug metabolizing capacity in human liver biopsy specimens: support for the intact hepatocyte theory. Hepatology 1991; 13:475-481.
33. Huet PM, Villeneuve JP. Determination of drug deposition in patients with cirrhosis. Hepatology 1983; 3:913-918.
34. Lindskov J. The quantitative liver function as measured by the galactose elimination capacity. II. Prognostic value and changes during disease in patients with cirrhosis. Acta Med Scand 1982; 212:303-308.
35. Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: a comparison with the Mayo model. Hepatology 1991; 14:504-510.
36. Reichen J. MEGX test in hepatology: the long sought ultimate quantitative liver function test? J Hepatol 1993; 19:4-7.
37. Meyer-Wyss B, Renner E, Luo H, Scholer A. Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests. J Hepatol 1993; 19:133-139.
38. Merkel C, Gatta A, Zoli M, Bolognesi M, Angeli P, Iervese T, et al. Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci 1991; 36:1197-1203.
39. Millikan WJ, Henderson JM, Stuart MT, Warren WD, Marsh JW. Change in hepatic function, hemodinamics and morphology after liver transplant. Physiological effect of therapy. Ann Surg 1989; 209:513-525.
40. Oellerich M, Burdelski M, Lautz HU, Binder L, Pichlmayr R. Predictors of one-year pretransplant survival in patients with cirrhosis. Hepatology 1991; 14:1029-1034.
41. Aebli N, Reichen J. The prognostic value of the serial determination of galactose elimination capacity in chronic active hepatitis. Schweiz Med Wochenschr 1991; 121:970-976.
42. Testa R, Valente U, Risso D, Caglieris S, Giannini E, Fasoli A, et al. Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis? Eur J Gastroenterol Hepatol 1999; 11:559-563.